Pfizer sees emergency use filing for Covid-19 vaccine after U.S. election

Pfizer sees emergency use filing for Covid-19 vaccine after U.S. election

PUBLISHED FRI, OCT 16 20206:29 AM EDT 
UPDATED FRI, OCT 16 20208:22 AM EDT

(CNBC) Pfizer said on Friday it may file for authorization of the Covid-19 vaccine it is developing with German partner BioNTech in late November, making it unlikely a vaccine will be available before U.S. elections as President Donald Trump has promised.

The regulatory filing for the vaccine could come as soon as safety data is available, possibly in the third week of November, Pfizer said, lifting the company’s shares and the broader U.S. stock market.

The timeline now allows for a possible U.S. authorization of a coronavirus vaccine this year, a key step in controlling the Covid-19 pandemic, which has killed more than a million people and ravaged the global economy. Read more...